Richard E. Nettles

8.1k total citations · 2 hit papers
39 papers, 5.9k citations indexed

About

Richard E. Nettles is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Richard E. Nettles has authored 39 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Infectious Diseases, 21 papers in Virology and 16 papers in Epidemiology. Recurrent topics in Richard E. Nettles's work include HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (20 papers) and HIV/AIDS Research and Interventions (12 papers). Richard E. Nettles is often cited by papers focused on HIV/AIDS drug development and treatment (21 papers), HIV Research and Treatment (20 papers) and HIV/AIDS Research and Interventions (12 papers). Richard E. Nettles collaborates with scholars based in United States, Germany and United Kingdom. Richard E. Nettles's co-authors include Daniel J. Sexton, Jingxiao Li, Thomas M. Bashore, Thomas Ryan, Vance G. Fowler, Nathan W. Mick, Tara L. Kieffer, Robert F. Siliciano, Dennis M. Grasela and Stuart C. Ray and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Richard E. Nettles

39 papers receiving 5.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis

2000 2.9k citations Daniel J. Sexton, Richard E. Nettles et al. Clinical Infectious Diseases profile →
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

2010 689 citations Min Gao, Richard E. Nettles et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard E. Nettles United States	25	3.9k	3.2k	1.4k	1.4k	1.2k	39	5.9k
Esteban Ribera Spain	40	2.3k 0.6×	3.0k 0.9×	609 0.4×	1.7k 1.2×	484 0.4×	231	5.5k
Antonio Rivero Spain	40	3.3k 0.8×	2.6k 0.8×	299 0.2×	749 0.5×	2.7k 2.3×	307	6.3k
Giampiero Carosi Italy	38	7.4k 1.9×	3.1k 1.0×	510 0.4×	933 0.7×	7.3k 6.1×	164	10.7k
Milos Opravil Switzerland	42	2.3k 0.6×	4.5k 1.4×	248 0.2×	3.6k 2.5×	607 0.5×	145	7.2k
Tomàs Pumarola Spain	35	2.5k 0.6×	2.2k 0.7×	475 0.3×	1.4k 1.0×	259 0.2×	293	5.0k
Fredy Suter Italy	26	1.5k 0.4×	1.6k 0.5×	404 0.3×	658 0.5×	540 0.5×	77	2.8k
Pierre‐Marie Girard France	50	2.8k 0.7×	3.6k 1.1×	267 0.2×	2.9k 2.0×	1.5k 1.2×	243	7.2k
Rob Schuurman Netherlands	48	3.1k 0.8×	5.0k 1.5×	268 0.2×	3.7k 2.6×	424 0.4×	163	7.8k
Gerd Fätkenheuer Germany	44	1.6k 0.4×	3.5k 1.1×	393 0.3×	2.4k 1.7×	270 0.2×	207	6.4k
Sunwen Chou United States	52	7.3k 1.8×	1.8k 0.5×	327 0.2×	1.1k 0.8×	644 0.5×	120	8.4k

Countries citing papers authored by Richard E. Nettles

Since Specialization

Citations

This map shows the geographic impact of Richard E. Nettles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard E. Nettles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard E. Nettles more than expected).

Fields of papers citing papers by Richard E. Nettles

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard E. Nettles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard E. Nettles. The network helps show where Richard E. Nettles may publish in the future.

Co-authorship network of co-authors of Richard E. Nettles

This figure shows the co-authorship network connecting the top 25 collaborators of Richard E. Nettles. A scholar is included among the top collaborators of Richard E. Nettles based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard E. Nettles. Richard E. Nettles is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kagan, Ron M., et al.. (2019). Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017. AIDS Research and Human Retroviruses. 35(8). 698–709. 17 indexed citations

Huhn, Gregory, Joseph J. Eron, Pierre‐Marie Girard, et al.. (2019). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. AIDS Research and Therapy. 16(1). 23–23. 6 indexed citations

Brown, Kimberley, et al.. (2018). Prevalence of Darunavir Resistance in the United States from 2010 to 2017. AIDS Research and Human Retroviruses. 34(12). 1036–1043. 9 indexed citations

Opsomer, Magda, Dessislava I. Dimitrova, Simon Vanveggel, et al.. (2018). Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir. Drugs in R&D. 18(3). 199–210. 9 indexed citations

Brown, Kimberley, et al.. (2017). Treating Older HIV-1-infected Subjects With Cobicistat-boosted Darunavir in a 48-week Phase 3 Trial. Reviews on Recent Clinical Trials. 12(3). 174–181. 1 indexed citations

Brown, Jonathan, Caly Chien, Peter Timmins, et al.. (2013). Compartmental Absorption Modeling and Site of Absorption Studies to Determine Feasibility of an Extended-Release Formulation of an HIV-1 Attachment Inhibitor Phosphate Ester Prodrug. Journal of Pharmaceutical Sciences. 102(6). 1742–1751. 44 indexed citations

Guedj, Jérémie, Harel Dahari, Libin Rong, et al.. (2013). Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proceedings of the National Academy of Sciences. 110(10). 3991–3996. 247 indexed citations

Sun, Jin-Hua, Donald R. O’Boyle, Yan Zhang, et al.. (2012). Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5a replication complex inhibitor, BMS-790052. Hepatology. 55(6). 1692–1699. 41 indexed citations

Gao, Min, Richard E. Nettles, Makonen Belema, et al.. (2010). Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 465(7294). 96–100. 689 indexed citations breakdown →

10.

Fridell, Robert A., Chunfu Wang, Jin-Hua Sun, et al.. (2010). Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations. Hepatology. 54(6). 1924–1935. 186 indexed citations

11.

Kieffer, Tara L., et al.. (2006). HIV-1 viral load blips are of limited clinical significance. Journal of Antimicrobial Chemotherapy. 57(5). 803–805. 86 indexed citations

12.

Nettles, Richard E., Tara L. Kieffer, Joseph Cofrancesco, et al.. (2005). Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART. HIV Clinical Trials. 6(5). 262–271. 2 indexed citations

13.

Nettles, Richard E.. (2005). Intermittent HIV-1 Viremia (Blips) and Drug Resistance in Patients Receiving HAART. JAMA. 293(7). 817–817. 294 indexed citations

14.

Kieffer, Tara L., et al.. (2005). G→A Hypermutation in Protease and Reverse Transcriptase Regions of Human Immunodeficiency Virus Type 1 Residing in Resting CD4 ⁺ T Cells In Vivo. Journal of Virology. 79(3). 1975–1980. 142 indexed citations

15.

Nettles, Richard E., Tara L. Kieffer, Joseph Cofrancesco, et al.. (2004). Genotypic Resistance in HIV‐1–Infected Patients with Persistently Detectable Low‐Level Viremia while Receiving Highly Active Antiretroviral Therapy. Clinical Infectious Diseases. 39(7). 1030–1037. 59 indexed citations

16.

Nettles, Richard E., Karla Alwood, Gina Maltas, et al.. (2004). Risk Factors for Relapse and Acquired Rifamycin Resistance after Directly Observed Tuberculosis Treatment: A Comparison by HIV Serostatus and Rifamycin Use. Clinical Infectious Diseases. 38(5). 731–736. 61 indexed citations

17.

Meine, Trip J., Richard E. Nettles, Deverick J. Anderson, et al.. (2001). Cardiac conduction abnormalities in endocarditis defined by the Duke criteria. American Heart Journal. 142(2). 280–285. 27 indexed citations

18.

Nettles, Richard E., et al.. (1997). Community-Acquired Prosthetic Valve Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Clinical Infectious Diseases. 24(6). 1272–1272. 1 indexed citations

19.

Nettles, Richard E. & Daniel J. Sexton. (1997). Successful Treatment ofEdwardsiella tardaProsthetic Valve Endocarditis in a Patient with AIDS. Clinical Infectious Diseases. 25(4). 918–919. 16 indexed citations

20.

Nettles, Richard E., David E. McCarty, G. Ralph Corey, Jennifer S. Li, & Daniel J. Sexton. (1997). An Evaluation of the Duke Criteria in 25 Pathologically Confirmed Cases of Prosthetic Valve Endocarditis. Clinical Infectious Diseases. 25(6). 1401–1403. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact